KPV is a synthetic tripeptide fragment of alpha-melanocyte-stimulating hormone. Cell and animal research has explored PepT1 transport and inflammatory signaling. Human safety, effectiveness, and dosing have not been established.
Coming soonComing soon
Mechanism education without turning preclinical findings into promises.
KPV is the Lys-Pro-Val tripeptide fragment of alpha-melanocyte-stimulating hormone. It is a defined peptide sequence, not the full parent hormone.
In intestinal epithelial and immune-cell experiments, researchers studied KPV transport through PepT1 and its relationship to NF-kB and MAP-kinase signaling. These are preclinical mechanism findings.
FDA identified no human exposure data, human pharmacokinetic studies, or clinical trials for KPV. Animal and ex-vivo findings do not establish human benefits, and one 2026 mouse study found no benefit from oral free KPV on reported disease measures.
A licensed provider must determine whether a compounded KPV protocol is appropriate. This option is coming soon. Pricing and protocol details will be confirmed when it opens.
Prescribed only when a licensed provider determines it is appropriate based on your history, medications, and treatment goals.
When prescribed, your medication is prepared by and shipped directly from a licensed U.S. pharmacy in discreet packaging.
Each product page separates mechanism research from human evidence so the unknowns stay visible.
Message your care team with questions about your protocol, refills, or side effects.
Get started in 4 simple steps. No office visits required.
A 5-minute online health questionnaire, no appointment, no waiting room.
A licensed provider in your state reviews your history and prescribes if appropriate.
When prescribed, your medication ships from a licensed U.S. pharmacy in discreet packaging.
Message your care team anytime. Dose questions and refills are handled online.
KPV evidence is preclinical. FDA identified no human administration data, and findings from engineered proKPV compounds cannot be attributed to free KPV.
No. This compounded medication is not FDA-approved. Compounded drugs are prepared for individual patients, and FDA does not verify their safety, effectiveness, or quality before marketing.
When this option opens, a licensed provider will review your medical history, medications, and goals before deciding whether to prescribe.
This option is coming soon. Pricing and provider-directed protocol details will be confirmed when it opens.